Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 15/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 15/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3158506 | 0.82 | PTGS2 (0.54) | MTNR1AMTNR1BPOLBTDP1PTGS2 | |
| SCHEMBL1712179 | 0.81 | MTNR1A (0.39) | MTNR1AMTNR1BPOLBTDP1PTGS2 | |
| SCHEMBL1712516 | 0.80 | MTNR1A (0.37) | MTNR1AMTNR1BPTGS2HTR2C | |
| SCHEMBL1712254 | 0.80 | MTNR1A (0.37) | MTNR1AMTNR1BPTGS2HTR2C | |
| SCHEMBL28792431 | 0.77 | MTNR1A (0.38) | MTNR1AMTNR1BPTGS2HTR2C | |
| SCHEMBL15875469 | 0.76 | MTNR1A (0.49) | MTNR1AMTNR1BPOLBTDP1PTGS2 | |
| SCHEMBL3228913 | 0.75 | MTNR1A (0.40) | MTNR1AMTNR1BPOLBTDP1PTGS2 | |
| SCHEMBL3141865 | 0.75 | CLK1 (0.45) | MTNR1AMTNR1BPTGS2HTR2C | |
| SCHEMBL3220236 | 0.74 | POLB (0.38) | MTNR1AMTNR1BPOLBTDP1PTGS2 | |
| SCHEMBL15548752 | 0.72 | POLB (0.44) | MTNR1AMTNR1BPOLBTDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2136807-B1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LTD (GB) | 2010-11-03 | — | — | EP | disclosed |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| EP-1954697-B1 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-02-24 | — | — | EP | disclosed |
| EP-2136807-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| US-20080280892-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| WO-2008125594-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
| EP-1980251-A1 | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| EP-1954697-A2 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007081597-A2 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | NQO2, MT-ND1, SDHB | MTNR1A 1695/4885MTNR1B 1409/4885POLB 312/4885 |
| US-20080280892-A1 | Compounds | NRDC, NACA, NAA50 | MTNR1A 2151/4885MTNR1B 1480/4885POLB 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.